AU2008298987B2 - Method of inhibiting clostridium difficile by administration of oritavancin - Google Patents

Method of inhibiting clostridium difficile by administration of oritavancin Download PDF

Info

Publication number
AU2008298987B2
AU2008298987B2 AU2008298987A AU2008298987A AU2008298987B2 AU 2008298987 B2 AU2008298987 B2 AU 2008298987B2 AU 2008298987 A AU2008298987 A AU 2008298987A AU 2008298987 A AU2008298987 A AU 2008298987A AU 2008298987 B2 AU2008298987 B2 AU 2008298987B2
Authority
AU
Australia
Prior art keywords
difficile
oritavancin
glycopeptide antibiotic
subject
spore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008298987A
Other languages
English (en)
Other versions
AU2008298987A1 (en
Inventor
Simon Baines
Dario Lehoux
Thomas R. Parr
Mark Harvey Wilcox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of AU2008298987A1 publication Critical patent/AU2008298987A1/en
Assigned to TARGANTA THERAPEUTICS CORP., THE MEDICINES COMPANY reassignment TARGANTA THERAPEUTICS CORP. Request for Assignment Assignors: TARGANTA THERAPEUTICS CORP., UNIVERSITY OF LEEDS
Application granted granted Critical
Publication of AU2008298987B2 publication Critical patent/AU2008298987B2/en
Assigned to THE MEDICINES COMPANY reassignment THE MEDICINES COMPANY Request for Assignment Assignors: THE MEDICINES COMPANY, TARGANTA THERAPEUTICS CORP.
Assigned to MELINTA THERAPEUTICS, INC. reassignment MELINTA THERAPEUTICS, INC. Request for Assignment Assignors: THE MEDICINES COMPANY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008298987A 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin Active AU2008298987B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97176607P 2007-09-12 2007-09-12
US60/971,766 2007-09-12
PCT/US2008/075949 WO2009036121A1 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Publications (2)

Publication Number Publication Date
AU2008298987A1 AU2008298987A1 (en) 2009-03-19
AU2008298987B2 true AU2008298987B2 (en) 2013-12-05

Family

ID=40452464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008298987A Active AU2008298987B2 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Country Status (9)

Country Link
US (3) US8518873B2 (enExample)
EP (1) EP2195004B1 (enExample)
JP (1) JP5591112B2 (enExample)
CN (1) CN102316885A (enExample)
AU (1) AU2008298987B2 (enExample)
CA (1) CA2699550C (enExample)
EA (1) EA017564B1 (enExample)
ES (1) ES2535928T3 (enExample)
WO (1) WO2009036121A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699550C (en) * 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
WO2009126502A2 (en) 2008-04-08 2009-10-15 Targanta Therapeutics Corp. Methods of inhibiting and treating biofilms using glycopeptide antibiotics
PT2424559T (pt) 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
JP5986416B2 (ja) * 2012-04-11 2016-09-06 花王株式会社 皮膚外用剤
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (ko) * 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6553074B2 (ja) * 2014-10-14 2019-07-31 アーゼッド・エレクトロニック・マテリアルズ（ルクセンブルグ）ソシエテ・ア・レスポンサビリテ・リミテ レジストパターン処理用組成物およびそれを用いたパターン形成方法
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
KR20180111948A (ko) * 2016-02-18 2018-10-11 멜린타 테라퓨틱스, 인크. 오리타반신 제제
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
CN109069580A (zh) 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
CA3109900A1 (en) * 2018-08-17 2020-02-20 Universidad Andres Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile
KR102444119B1 (ko) * 2020-04-22 2022-09-16 주식회사 인트론바이오테크놀로지 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197333A1 (en) * 2003-12-23 2005-09-08 Van Duzer John H. Rifamycin analogs and uses thereof
US20070014849A1 (en) * 2002-06-06 2007-01-18 Daniela Jabes Use of ramoplanin to treat diseases associated with the use of antibiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
JP2006501310A (ja) * 2002-08-29 2006-01-12 アクティブバイオティクス インコーポレイティッド クロストリジウム・ディフィシレの感染およびそれに関係する疾患を治療するための方法および試薬
JP2009526069A (ja) * 2006-02-08 2009-07-16 バイオシネクサス インコーポレーティッド 細菌胞子の中和
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CA2699550C (en) * 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014849A1 (en) * 2002-06-06 2007-01-18 Daniela Jabes Use of ramoplanin to treat diseases associated with the use of antibiotics
US20050197333A1 (en) * 2003-12-23 2005-09-08 Van Duzer John H. Rifamycin analogs and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VAN BAMBEKE, F., Current Opinion in Investigational Drugs, 2006 (7):740-749. *
WARD, K.E., et al., Expert Opinion on Investigational Drugs, Ashley Publications LTD., London. 2006, Vol. 15, No.4, pages 417-429. *

Also Published As

Publication number Publication date
ES2535928T3 (es) 2015-05-19
EP2195004A1 (en) 2010-06-16
CA2699550A1 (en) 2009-03-19
US9220749B2 (en) 2015-12-29
US20130310308A1 (en) 2013-11-21
BRPI0816662A2 (pt) 2017-06-13
EA201000383A1 (ru) 2010-10-29
US8518873B2 (en) 2013-08-27
US20140100157A1 (en) 2014-04-10
EP2195004B1 (en) 2015-04-01
JP5591112B2 (ja) 2014-09-17
JP2010539179A (ja) 2010-12-16
US8629100B2 (en) 2014-01-14
CA2699550C (en) 2020-08-18
CN102316885A (zh) 2012-01-11
US20100311646A1 (en) 2010-12-09
EA017564B1 (ru) 2013-01-30
EP2195004A4 (en) 2011-12-28
AU2008298987A1 (en) 2009-03-19
WO2009036121A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
AU2008298987B2 (en) Method of inhibiting clostridium difficile by administration of oritavancin
ES2884673T3 (es) Oritavancina para inhibir y tratar biopelículas
AU2009285564B2 (en) Methods of treatment using single doses of oritavancin
CZ290578B6 (cs) Léčivo určené k léčbě infekce způsobené multidrogově-rezistentními kmeny stafylokoka, streptokoka nebo enterokoka
CA2664444C (en) Use of oritavancin for prevention and treatment of anthrax
WO2015031579A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
BRPI0816662B1 (pt) Método in vitro para inibir crescimento de esporo de c. difficile
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TARGANTA THERAPEUTICS CORP.; THE MEDICINES COMPANY

Free format text: FORMER APPLICANT(S): UNIVERSITY OF LEEDS; TARGANTA THERAPEUTICS CORP.

PC1 Assignment before grant (sect. 113)

Owner name: THE MEDICINES COMPANY

Free format text: FORMER APPLICANT(S): TARGANTA THERAPEUTICS CORP.; THE MEDICINES COMPANY

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MELINTA THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): THE MEDICINES COMPANY

GD Licence registered

Name of requester: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.